IL6 and COVID-19: When it comes to P2Y12 Receptor Antagonists, there is not much evidence of their COVID-19 use, however, its administration in cases of pneumonia can lead to a decrease in circulating platelet and leukocyte count, lower IL-6 levels and improved lung function and oxygen requirements [23].